Food interaction study of a new theophylline (Egifilin) 200 and 400 mg retard tablet in healthy volunteers

International Journal of Clinical Pharmacology and Therapeutics

Volumn 35, Issue 2, 1997, Pages 65-70

  Urmos I ^a   Grezal Gy ^a   Balogh Nemes, K ^a   Szallasi T ^a   Drabant, S ^a   Csorgo M ^a   Klebovich, I ^a  

^a EGIS PHARMACEUTICALS LTD   (Hungary)

Author keywords

400 mg retard tablet; Egifilin 200; Food interaction; HPLC UV; Pharmacokinetics; Theophylline

Indexed keywords

EGIFILIN; THEOPHYLLINE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; FOOD DRUG INTERACTION; HUMAN; HUMAN EXPERIMENT; MEAN RESIDENCE TIME; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ADULT; ANTI-ASTHMATIC AGENTS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FOOD-DRUG INTERACTIONS; HALF-LIFE; HUMANS; SPECTROPHOTOMETRY, ULTRAVIOLET; THEOPHYLLINE;

EID: 0344366131     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Bezzegh D, Fekete P, Tóth Z, Bor I, Fellner E 1987 United States Patent. Pat. No.: 4,647,599
2. Buick AR, Doing MV, Jeal SC, Land GS, McDowal RD 1990 Method validation in the bioanalytical laboratory. J Pharm Biomed Anal 8: 629-637
3. Blume HH, Midha KK 1995 Bio-International 2, bioavailability, bioequivalence and pharmacokinetic studies. Medpharm Scientific Publishers, Stuttgart
4. Comission of the European Communities (EC) 1992 Guidance for investigation of bioavailability and bioequivalence (Appendix III technical aspects of bioequivalence statistics). Brussels 111/54/1.5
5. Food and Drug Administration (FDA) 1992 Guidance statistical process for bioequivalence studies using a standard two-treatment crossover design. Division of Bioequivalence Office of generic drugs, Rockville, USA
6. Gennaro AR 1990 Remington's Pharmaceutical Sciences (18th ed). Mack Publishing. Easton, Pennsylvania, USA
7. Gibaldi M, Perrier D 1982 Pharmacokinetics. In: Drug and Pharmaceutical Sciences Vol 1. Marcel Dekker, New York
8. Gibaldi M, Prescott L 1983 Handbook of Clinical Pharmacokinetics. ADIS Health Sciences Press, New York
9. Gilman AG, Rall TW, Nies AS, Taylor P 1990 Goodman and Gilman's The Pharmacological Basis of Therapeutics (8th ed). Pergamon, Elmsford, NY
10. Hendeles L, Massanari M, Weinberger M 1985 Update on the pharmacodynamics and pharmacokinetics of theophylline. Chest 88: 103-111
11. Jonkman JHG 1989 Food interactions with sustained release theophylline preparations - a review. Clin Pharmacokin 16: 162-179
12. Nagy É, Benko S, Klebovich I 1991 Determination and validation of theophylline by high performance liquid chromatography in human plasma. Acta Pharm Hung 61: 169-174
13. Ogilvie RI 1978 Clinical pharmacokinetics of theophylline. Clin Pharmacokin 3: 267-293
14. Pedersen S, Möller-Petersen J 1985 Influence of food on the absorption of theophylline from a sustained release formulation (Somophyllin). Clin Allergy 15: 253-259
15. Riegelman S, Collier P 1980 The application of statistical moment theory to evaluation of in vivo dissolution time and absorption time. J Pharmacokin Biopharm 8: 509-534
16. Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, Layloff T, Viswanathan CT, Cook CE, McDowall RD, Pittman KA, Spector S 1991 Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Eur J Drug Metab Pharmacokin 16: 249-255
17. Schuirmann DJ 1987 A comparison of the two one-sided tests procedure and power approach for assessing the equivalence of average bioavailability. J Pharmacokin Biopharm 15: 657-680
18. Tallarida TJ, Murray RB 1986 Manual pharmacologic calculations. Springer, New York
19. Ürmös I, Grézal Gy, Benko S, Fekete P, Szállási T, Drabant S, Csörgo M, Klebovich I 1996 Comparative pharmacokinetics of new theophylline preparations as Egifilin 200 mg and 400 mg retard tablets after single dose in healthy volunteers. Drug Developm. Industr. Pharm. (submitted for publication)